A comparison of oral milri- none, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677 83. 208. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22: 955 62. 209. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin- converting-enzyme inhibitors: RADIANCE Study. N Engl J Med 1993;329:1 7. 210. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial brillation. N Engl J Med 2011;365: 981 92. 211. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial brillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial brillation and utter. Can J Cardiol 2011;27:74 90. 212. Risk factors for stroke and ef cacy of antithrombotic therapy in atrial brillation: analysis of pooled data from ve randomized controlled trials. Arch Intern Med 1994;154:1449 57. Erratum in: Arch Intern Med. 1994;154:2254. JACC Vol. 62, No. 16, 2013 Yancy et al. October 15, 2013:1495 539 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary 213. Hughes M, Lip GY. Stroke and thromboembolism in atrial brillation: a systematic review of stroke risk factors, risk strati cation schema and cost effectiveness data. Thromb Haemost 2008;99:295 304. 214. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial brillation. N Engl J Med 2009;361:1139 51. 215. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identi ed events in the RE-LY trial. N Engl J Med 2010;363:1875 6. 216. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial brillation. 